PTEN and neoplasm: As ASD-related mutations have been shown to decrease but not abrogate PTEN phosphatase activity (Rodriguez-Escudero et al., 2011), this high sensitivity should render our method a well-suited tool for testing ASD- and tumor-associated PTEN mutations.